Wuhan Hiteck Biological Pharma Co.,Ltd reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 546.64 million compared to CNY 392.37 million a year ago. Revenue was CNY 546.64 million compared to CNY 392.37 million a year ago.

Net income was CNY 18.82 million compared to CNY 18.64 million a year ago. Basic earnings per share from continuing operations was CNY 0.15 compared to CNY 0.18 a year ago. Diluted earnings per share from continuing operations was CNY 0.15 compared to CNY 0.18 a year ago.